Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Granisetron Hydrochloride Nasal Spray
- Development stage
- Phase 4
- Lead developer
- Maxinase Life Sciences
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Granisetron Hydrochloride Nasal Spray (GNS) is a pharmaceutical formulation containing Granisetron Hydrochloride, a selective serotonin 5-HT3 receptor antagonist. It is designed for intranasal administration and is being studied for its pharmacokinetics, safety, and tolerability. Granisetron is an antiemetic primarily used to prevent nausea and vomiting, particularly that induced by chemotherapy or radiotherapy.
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on Granisetron Hydrochloride Nasal Spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Granisetron Hydrochloride Nasal Spray.